Cargando…
Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity
Multiple studies have indicated that in addition to direct oncolysis, virotherapy promotes an antitumor cytotoxic T cell response important for efficacy. To study this phenomenon further, we tested three syngeneic murine sarcoma models that displayed varied degrees of permissiveness to oncolytic her...
Autores principales: | Leddon, Jennifer L, Chen, Chun-Yu, Currier, Mark A, Wang, Pin-Yi, Jung, Francesca A, Denton, Nicholas L, Cripe, Kevin M, Haworth, Kellie B, Arnold, Michael A, Gross, Amy C, Eubank, Timothy D, Goins, William F, Glorioso, Joseph C, Cohen, Justus B, Grandi, Paola, Hildeman, David A, Cripe, Timothy P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782947/ https://www.ncbi.nlm.nih.gov/pubmed/27119100 http://dx.doi.org/10.1038/mto.2014.10 |
Ejemplares similares
-
Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment
por: Denton, Nicholas L., et al.
Publicado: (2018) -
Expression of HSV-1 Receptors in EBV-Associated Lymphoproliferative Disease Determines Susceptibility to Oncolytic HSV
por: Wang, Pin-Yi, et al.
Publicado: (2012) -
Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?
por: Denton, Nicholas L., et al.
Publicado: (2016) -
Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy
por: Mamola, Joseph A., et al.
Publicado: (2023) -
VEGF Blockade Decreases Tumor Uptake of Systemic Oncolytic Herpes Virus but Enhances Therapeutic Efficacy When Given After Virotherapy
por: Eshun, Francis K., et al.
Publicado: (2010)